Company
Idogen AB
Headquarters: Lund, Sweden
Employees: 11
CEO: Mr. Anders Karlsson
Market Cap
kr12.8 Million
SEK as of Jan. 1, 2024
US$1.3 Million
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Idogen AB (publ), a biotechnology company, engages in the development of tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, or the body's own cells or tissues in Sweden. The company's advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed anti-drug antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplant rejection; and IDO AID for the treatment of autoimmune diseases. The company was founded in 2008 and is headquartered in Lund, Sweden.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Idogen AB has the following listings and related stock indices.
Stock: OMX: IDOGEN wb_incandescent